首页> 外国专利> Sustained-Release combination preparations for the treatment of diabetes mellitus having enhanced compliance and preparation method thereof

Sustained-Release combination preparations for the treatment of diabetes mellitus having enhanced compliance and preparation method thereof

机译:具有增强顺应性的治疗糖尿病的缓释组合制剂及其制备方法

摘要

The present invention relates to sustained-release complex preparations for the treatment of diabetes with improved drug compliance and to a method for preparing same. More particularly, the present invention relates to sustained-release complex oral preparations for the treatment of diabetes, which comprise: a) an inner layer that includes Metformin or pharmaceutically acceptable salts thereof, sustained-release carriers and a pharmaceutically acceptable excipient; b) an intermediate layer that does not include drugs and that includes a water-soluble polymer; and c) an outer layer that includes sulfonylurea-based drugs and a control release formulation, wherein Carbomer is used as the sustained-release carriers. According to the present invention, complex preparations for the treatment of diabetes, comprising the inner layer including Metformin, the intermediate layer and the outer layer including sulfonylurea-based drugs, use Carbomer as the sustained-release carriers of the inner layer, thus exhibiting the same release pattern as that of Amaryl Mex which has been used in conventional complex preparations for the treatment of diabetes. Furthermore, the greater part of the sustained-release carriers is decomposed after 24 hours, thus avoiding gastrointestinal tract disorders. The weight of the inner layer is minimized to reduce the size of a tablet to allow for ease of medicine taking, thus improving drug compliance of a patient.
机译:本发明涉及具有改善的药物顺应性的用于治疗糖尿病的缓释复合制剂及其制备方法。更具体地说,本发明涉及用于治疗糖尿病的缓释复合口服制剂,其包括:a)内层,其包含二甲双胍或其药学上可接受的盐,缓释载体和药学上可接受的赋形剂; b)不包含药物且包含水溶性聚合物的中间层; c)包含磺酰脲类药物和控释制剂的外层,其中卡波姆用作持续释放载体。根据本发明,用于治疗糖尿病的复杂制剂,其包括内含二甲双胍的内层,中间层和外含磺酰脲类药物的外层,使用卡波姆作为内层的缓释载体,从而显示出与Amaryl Mex的释放模式相同,后者已用于治疗糖尿病的常规复杂制剂中。此外,持续释放载体的大部分在24小时后分解,从而避免了胃肠道疾病。内层的重量被最小化以减小片剂的尺寸,以便于服用药物,从而改善了患者的药物依从性。

著录项

  • 公开/公告号KR101409330B1

    专利类型

  • 公开/公告日2014-06-18

    原文格式PDF

  • 申请/专利权人

    申请/专利号KR20120050202

  • 申请日2012-05-11

  • 分类号A61K9/22;A61K9/20;A61K31/155;A61P3/10;

  • 国家 KR

  • 入库时间 2022-08-21 15:40:40

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号